Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GV20-0251
- Development stage
- Phase 2
- Lead developer
- GV20 Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
GV20-0251 is a fully human, Fc-attenuated IgG1 monoclonal antibody developed by GV20 Therapeutics. It targets the immune checkpoint Immunoglobulin Superfamily Member 8 (IGSF8), acting as an antagonist to inhibit its function. By binding to IGSF8 expressed on various immune cells, GV20-0251 prevents the interaction of IGSF8 with its ligands, thereby enhancing natural killer (NK) cell-mediated cytotoxicity against malignant cells, upregulating dendritic cell antigen presentation, and increasing T cell activation. The drug is being investigated primarily for advanced and/or refractory solid tumor malignancies in Phase 1/2 clinical trials as both monotherapy and in combination with pembrolizumab (Keytruda). It represents the first AI-designed antibody against an AI-predicted target to enter clinical development[2][5][6][7].
- Other names
- anti-IGSF8 monoclonal antibody GV20-0251anti-IGSF-8 monoclonal antibody GV20-0251anti-IGSF 8 monoclonal antibody GV20-0251
02
Targets
IGSF8 (Immunoglobulin superfamily member 8)
Beyond the preview
Go deeper on GV20-0251.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GV20-0251.